Upcoming Webinar
RET Fusion-Positive Metastatic NSCLC: the Role of Pralsetinib and an Update from the ARROW Clinical Trial
Date: December 3, 2025 | 2:00 PM
When: Wednesday, December 3 | 2 p.m. EST
Presenters: Cynthia Villarimo-Schauer, PhD | Rigel Medical Affairs
RET fusion–positive metastatic NSCLC is a small but important patient group — and staying current on the science behind RET alterations and targeted options like pralsetinib is key to making confident treatment decisions.
In this session, Cynthia Villarimo-Schauer, PhD, takes a clear, practical look at the biology, guidelines, and data shaping care today, including:
- RET biology + prevalence in NSCLC and why it matters
- Current NCCN guidance and the role of biomarker testing
- Efficacy and safety findings for pralsetinib from the Phase II ARROW trial
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
RET Fusion-Positive Metastatic NSCLC: the Role of Pralsetinib and an Update from the ARROW Clinical Trial
December 3, 2025 | 2:00 PM







